Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2025 · 10-Q
Revenue$109.00K$109.00K−46.8% vs Q1 2024 Net Income-$13.43M-$13.43MN/M vs Q1 2024 EPS Diluted-$0.20-$0.20N/M vs Q1 2024 Operating Income-$14,382,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Margins · derivedOperating margin-13194.5%−7861.3 pt vs Q1 2024
Net margin-12324.8%−7441.4 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end